Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1864 1
1873 1
1875 1
1876 1
1886 1
1889 1
1891 1
1892 1
1894 2
1895 3
1896 3
1897 3
1898 1
1899 2
1900 1
1901 3
1902 3
1903 3
1904 1
1905 1
1906 2
1907 1
1908 1
1912 1
1923 1
1924 1
1925 1
1928 1
1930 2
1940 1
1946 3
1948 3
1949 1
1950 3
1951 2
1952 2
1953 2
1954 5
1955 1
1956 4
1957 1
1958 2
1959 2
1960 5
1961 10
1962 8
1963 4
1964 11
1965 15
1966 7
1967 10
1968 14
1969 22
1970 19
1971 20
1972 19
1973 10
1974 6
1975 11
1976 18
1977 16
1978 14
1979 16
1980 22
1981 18
1982 16
1983 32
1984 25
1985 32
1986 26
1987 26
1988 35
1989 43
1990 52
1991 41
1992 51
1993 56
1994 55
1995 57
1996 52
1997 52
1998 50
1999 51
2000 57
2001 57
2002 57
2003 62
2004 68
2005 68
2006 84
2007 72
2008 82
2009 82
2010 93
2011 114
2012 116
2013 154
2014 158
2015 136
2016 126
2017 130
2018 130
2019 166
2020 161
2021 149
2022 140
2023 120
2024 119
2025 115
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,572 results

Results by year

Filters applied: . Clear all
Page 1
Medullary Thyroid Cancer: Updates and Challenges.
Gild ML, Clifton-Bligh RJ, Wirth LJ, Robinson BG. Gild ML, et al. Among authors: robinson bg. Endocr Rev. 2023 Sep 15;44(5):934-946. doi: 10.1210/endrev/bnad013. Endocr Rev. 2023. PMID: 37204852 Free PMC article.
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma.
Zeng PYF, Prokopec SD, Lai SY, Pinto N, Chan-Seng-Yue MA, Clifton-Bligh R, Williams MD, Howlett CJ, Plantinga P, Cecchini MJ, Lam AK, Siddiqui I, Wang J, Sun RX, Watson JD, Korah R, Carling T, Agrawal N, Cipriani N, Ball D, Nelkin B, Rooper LM, Bishop JA, Garnis C, Berean K, Nicolson NG, Weinberger P, Henderson YC, Lalansingh CM, Tian M, Yamaguchi TN, Livingstone J, Salcedo A, Patel K, Vizeacoumar F, Datti A, Xi L, Nikiforov YE, Smallridge R, Copland JA, Marlow LA, Hyrcza MD, Delbridge L, Sidhu S, Sywak M, Robinson B, Fung K, Ghasemi F, Kwan K, MacNeil SD, Mendez A, Palma DA, Khan MI, Shaikh M, Ruicci KM, Wehrli B, Winquist E, Yoo J, Mymryk JS, Rocco JW, Wheeler D, Scherer S, Giordano TJ, Barrett JW, Faquin WC, Gill AJ, Clayman G, Boutros PC, Nichols AC. Zeng PYF, et al. Among authors: robinson b. Cell Rep. 2024 Mar 26;43(3):113826. doi: 10.1016/j.celrep.2024.113826. Epub 2024 Feb 26. Cell Rep. 2024. PMID: 38412093 Free PMC article.
Distinct mesenchymal cell states mediate prostate cancer progression.
Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, Socciarelli F, Van Emmenis L, Rodrigues S, Fidalgo-Ribeiro C, Nuzzo PV, Brady NJ, Dinalankara W, Jere M, Valencia I, Saladino C, Stone J, Unkenholz C, Garner R, Alexanderani MK, Khani F, de Almeida FN, Abate-Shen C, Greenblatt MB, Rickman DS, Barbieri CE, Robinson BD, Marchionni L, Loda M. Pakula H, et al. Among authors: robinson bd. Nat Commun. 2024 Jan 8;15(1):363. doi: 10.1038/s41467-023-44210-1. Nat Commun. 2024. PMID: 38191471 Free PMC article.
Pheochromocytoma in MEN2.
Gild ML, Do K, Tsang VHM, Tacon LJ, Clifton-Bligh RJ, Robinson BG. Gild ML, et al. Among authors: robinson bg. Recent Results Cancer Res. 2025;223:211-235. doi: 10.1007/978-3-031-80396-3_8. Recent Results Cancer Res. 2025. PMID: 40102259 Review.
Authors' Reply.
Guedes M, Robinson B, Bieber B, Pecoits-Filho R. Guedes M, et al. Among authors: robinson b. J Am Soc Nephrol. 2022 Mar;33(3):655-656. doi: 10.1681/ASN.2021111504. Epub 2022 Jan 19. J Am Soc Nephrol. 2022. PMID: 35046129 Free PMC article. No abstract available.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. Among authors: robinson bg. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.
Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Chen X, Socciarelli F, Frankenstein Z, Zou M, Pannellini T, Chen Y, Gardner K, Robinson BD, de Bono J, Abate-Shen C, Rubin MA, Loda M, Sawyers CL, Califano A, Lu C, Shen MM. Li JJ, et al. Among authors: robinson bd. bioRxiv [Preprint]. 2023 Jul 19:2023.07.18.549585. doi: 10.1101/2023.07.18.549585. bioRxiv. 2023. PMID: 37502956 Free PMC article. Preprint.
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Sen S, Oliver JW, Banerjee K, Keam B, Capdevila J. Brose MS, et al. Among authors: robinson bg. Cancer. 2022 Dec 15;128(24):4203-4212. doi: 10.1002/cncr.34493. Epub 2022 Oct 19. Cancer. 2022. PMID: 36259380 Free PMC article. Clinical Trial.
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Brose MS, et al. Among authors: robinson b. Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5. Lancet Oncol. 2021. PMID: 34237250 Clinical Trial.
3,572 results